List of Excipients in Branded Drug PRINIVIL

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Merck Sharp & Dohme Corp	PRINIVIL	lisinopril	0006-0019	DIBASIC CALCIUM PHOSPHATE DIHYDRATE
Merck Sharp & Dohme Corp	PRINIVIL	lisinopril	0006-0019	MAGNESIUM STEARATE
Merck Sharp & Dohme Corp	PRINIVIL	lisinopril	0006-0019	MANNITOL
Merck Sharp & Dohme Corp	PRINIVIL	lisinopril	0006-0019	STARCH, CORN

PRINIVIL Excipient Strategy and Commercial Opportunities for Lisinopril Tablets

Last updated: September 25, 2026

PRINIVIL is the former Merck brand for lisinopril, an angiotensin-converting enzyme inhibitor used for hypertension, heart failure, and acute myocardial infarction. Its commercial opportunity is no longer a branded-patent play. The value is in low-cost generic lisinopril, differentiated excipient systems, orally disintegrating or dispersible formats, pediatric presentations, and contract manufacturing. The legacy PRINIVIL formulation uses conventional, low-cost tablet excipients, including calcium phosphate, mannitol, starch, magnesium stearate, and, in selected strengths, red ferric oxide [1].

What is PRINIVIL and which excipients does it contain?

PRINIVIL contains lisinopril, supplied as immediate-release oral tablets. The product was developed for once-daily administration across multiple dose strengths, commonly 5 mg, 10 mg, and 20 mg.

The labeled inactive ingredients include:

Excipient	Likely formulation function	Commercial relevance
Calcium phosphate	Diluent, compression aid	Supports low-cost direct compression
Mannitol	Diluent, mouthfeel modifier	Useful for palatability and orally dispersible formats
Starch	Binder and disintegration aid	Supports tablet breakup and manufacturability
Magnesium stearate	Lubricant	Controls ejection force and tooling adhesion
Red ferric oxide	Colorant	Supports strength identification and product differentiation

The combination is a conventional immediate-release tablet platform. It does not rely on modified-release polymers, lipid carriers, enteric coatings, or complex delivery technology.

What is the role of each PRINIVIL excipient?

Calcium phosphate provides bulk and mechanical strength. Mannitol adds soluble tablet mass and can improve mouthfeel if the tablet is chewed or dispersed. Starch contributes to binding during granulation and disintegration after administration. Magnesium stearate reduces friction during tablet compression and ejection, but excessive levels or prolonged blending can reduce tablet wettability and dissolution. Red ferric oxide provides visual differentiation between dose strengths.

The formulation has a relatively straightforward development profile. A generic manufacturer can usually reproduce the dosage form without adopting the exact qualitative and quantitative composition, provided the finished product meets applicable quality, bioequivalence, dissolution, stability, and manufacturing requirements.

When did PRINIVIL lose exclusivity?

PRINIVIL no longer has meaningful market exclusivity. Lisinopril is an established generic active ingredient with multiple approved manufacturers and extensive historical clinical use.

The original product patents and regulatory exclusivity periods expired long ago. Current commercial access is governed primarily by abbreviated new drug application, or ANDA, competition rather than by a live PRINIVIL patent barrier.

Exclusivity category	Current position
Brand patent exclusivity	Expired
New chemical entity exclusivity	Expired
Pediatric exclusivity	Expired or no longer commercially relevant
Generic availability	Broad
Biosimilar pathway	Not applicable
Current branded PRINIVIL growth thesis	Limited
Generic formulation opportunity	Active, but price competitive

The FDA approved lisinopril in the 1980s. The product’s long market history means that most commercial value has migrated from originator sales to generic volume, manufacturing efficiency, and channel access [1, 2].

What is the FDA regulatory status of PRINIVIL and lisinopril?

FDA-approved lisinopril products are conventional prescription tablets. The approved indications include:

• Hypertension in adults and pediatric patients six years of age and older
• Reduction of mortality in hemodynamically stable patients after acute myocardial infarction
• Treatment of systolic heart failure as an adjunct to diuretics and, where appropriate, digitalis

The FDA-approved reference product historically associated with lisinopril is PRINIVIL. ZESTRIL, another lisinopril brand, was also marketed. Generic lisinopril tablets are approved through the ANDA pathway by demonstrating pharmaceutical equivalence and bioequivalence to the reference listed drug.

Lisinopril is a synthetic peptide derivative that is active without hepatic conversion to an active metabolite. It is hydrophilic and is administered orally. These characteristics reduce the commercial need for advanced lipid or prodrug delivery systems, although they leave room for improved patient acceptability and administration formats.

What is the Orange Book status of PRINIVIL?

The Orange Book framework remains relevant for reference-product identification, therapeutic equivalence, and any listed patents or exclusivities. PRINIVIL is not protected by a commercially meaningful current patent estate that prevents routine generic competition.

For a lisinopril product sponsor, the principal Orange Book considerations are:

1. Identification of the relevant reference listed drug.
2. Confirmation of the dosage form and strength.
3. Therapeutic-equivalence designation for competing products.
4. Review of any listed patents or regulatory exclusivities associated with a specific reference product.
5. Assessment of whether a proposed product is an ANDA, 505(b)(2), or supplemental product.

A standard lisinopril tablet generally has a clearer regulatory path than a reformulated or novel-delivery product. A product that changes route of administration, release profile, dosing frequency, or clinical use may require a different FDA strategy and could face additional clinical or regulatory requirements [2, 3].

What formulations are protected by PRINIVIL patents?

No commercially significant active PRINIVIL formulation patent is generally understood to block development of standard lisinopril tablets. The original formulation is technologically simple and has been overtaken by generic versions.

Potentially protectable formulation features today would need to arise from a new product design rather than from the historical PRINIVIL tablet. Candidates include:

Orally disintegrating lisinopril

An orally disintegrating tablet could target patients with dysphagia, geriatric patients, pediatric patients, and patients who have difficulty swallowing conventional tablets. Mannitol, crospovidone, croscarmellose sodium, low-substituted hydroxypropyl cellulose, and carefully controlled lubricant levels could support rapid disintegration.

The main development risks are moisture sensitivity, friability, taste, and dose uniformity. Lisinopril has a bitter or unpleasant taste profile, so taste masking would be necessary for a true mouth-dissolving product.

Pediatric dispersible tablets

The FDA label includes pediatric hypertension use for patients six years of age and older. A dispersible tablet could improve dose administration and reduce tablet-splitting errors. The commercial opportunity is narrower than for adult hypertension, but pediatric dosage flexibility can support hospital and specialty-pharmacy channels.

A dispersible product may use a scored tablet, multiparticulate dispersion, or sachet format. Excipients must be screened for age-related tolerability and dosing accuracy.

Liquid oral formulation

An extemporaneous or commercial oral solution could serve patients who cannot swallow tablets. The principal technical problem is chemical stability in an aqueous environment. Lisinopril formulations would require control of pH, microbial risk, preservative compatibility, container interaction, and shelf life.

A liquid product could command a higher price than standard tablets, but its market is smaller and its regulatory burden is greater.

Fixed-dose combinations

Lisinopril has been combined with hydrochlorothiazide and other antihypertensive agents. Fixed-dose combinations can reduce pill burden and improve adherence, but they face crowded generic competition. Opportunities are strongest where a combination improves dose titration, packaging, or patient segmentation.

Abuse-deterrent or modified-release products

These are weak opportunities for lisinopril. The drug is not a controlled substance, and its clinical use does not create a strong abuse-deterrence rationale. Modified release would need to demonstrate a meaningful clinical or adherence benefit over inexpensive once-daily immediate-release tablets.

How strong is the PRINIVIL patent estate?

The historical PRINIVIL patent estate is commercially weak because the core active ingredient, conventional tablet, and major indications are long established.

Patent-estate factor	Assessment
Core composition-of-matter protection	Expired
Conventional tablet protection	Expired or commercially ineffective
Basic antihypertensive use	Expired or difficult to enforce
Generic substitution barriers	Low
Formulation design-around risk	High
Opportunity for new patents	New dosage forms and combinations only
Litigation leverage	Low for standard tablets

A new sponsor would need to patent a concrete technical feature, such as a stable liquid composition, rapid-disintegration system, novel taste-masking matrix, manufacturing process, or clinically differentiated combination. Broad claims covering lisinopril tablets would face substantial validity and obviousness risk because the active ingredient and conventional dosage forms are well known.

Which companies are challenging PRINIVIL?

PRINIVIL has already been challenged through the normal generic substitution process. The relevant competitive group consists of generic manufacturers that have marketed lisinopril tablets or lisinopril/hydrochlorothiazide products, including companies such as Teva, Lupin, Sandoz, Zydus, Solco Healthcare, and other ANDA sponsors.

The competitive threat is not concentrated in a single Paragraph IV challenger. It is distributed across numerous approved or historically approved generic suppliers.

What is the Paragraph IV risk for lisinopril?

Paragraph IV risk is limited for a standard lisinopril tablet because the principal exclusivity barriers have expired. A new ANDA sponsor would ordinarily focus on:

• Reference listed drug selection
• Bioequivalence
• CMC reproducibility
• Stability
• Manufacturing economics
• Supply reliability
• Therapeutic-equivalence status

Paragraph IV litigation could still arise around a newer formulation, combination product, or method-of-use patent. It is unlikely to create durable protection for an ordinary immediate-release lisinopril tablet.

What manufacturing and excipient barriers affect lisinopril?

The active ingredient and tablet process are relatively accessible. Commercial differentiation therefore depends on process capability and supply economics.

Key manufacturing risks include:

• Uniform distribution of low-dose lisinopril
• Control of blend segregation
• Tablet hardness and friability
• Lubricant overblending
• Dissolution consistency
• Moisture control
• Stability of the finished product
• Color uniformity across strengths
• Cross-contamination controls in multiproduct facilities

A 5 mg tablet creates greater content-uniformity pressure than a 20 mg tablet because the active load is small relative to total tablet mass. A manufacturer may use geometric dilution, wet granulation, dry granulation, or specialized blending to improve uniformity.

Calcium phosphate and mannitol can support robust compression, but the selected grade affects flow, compactability, and dissolution. Starch can improve disintegration, although its performance depends on source, moisture, and processing history. Magnesium stearate concentration and blending time require control because over-lubrication can delay wetting and dissolution.

What commercial opportunities exist for PRINIVIL excipients?

The strongest opportunities are platform-based rather than brand-based.

Opportunity	Target customer	Commercial attractiveness	Main barrier
Low-cost conventional tablet	Generic manufacturers	Moderate volume, low margin	Commodity pricing
Orally disintegrating tablet	Geriatric, pediatric, institutional markets	Moderate	Taste and moisture stability
Pediatric dispersible tablet	Hospitals and caregivers	Moderate niche	Smaller market
Oral liquid	Long-term care and dysphagia patients	Niche premium	Stability and microbial control
Fixed-dose combination	Generic cardiovascular companies	Moderate	Crowded market
Direct-compression excipient system	CDMOs and ANDA sponsors	Moderate	Need for validated performance
Taste-masking excipient platform	Reformulation companies	Selective premium	Lisinopril bitterness
Low-moisture packaging system	Generic manufacturers	Incremental	Packaging cost

Excipient suppliers can pursue a co-development model in which they provide a prequalified platform using mannitol, starch, superdisintegrant, and lubricant combinations. The value proposition is shorter formulation screening and more predictable scale-up.

A supplier could also develop a color-free platform for customers seeking simplified labeling, reduced colorant exposure, or a common tablet appearance across strengths. That opportunity is commercially modest but may help manufacturers reduce raw-material complexity.

How does PRINIVIL compare with competing ACE inhibitor products?

Lisinopril competes with enalapril, ramipril, perindopril, benazepril, and other ACE inhibitors, as well as angiotensin receptor blockers and newer antihypertensive combinations.

Product	Formulation opportunity	Generic competition	Differentiation potential
Lisinopril	ODT, liquid, dispersible, combinations	High	Moderate
Enalapril	Liquid and pediatric formats	High	Moderate
Ramipril	Capsules and combinations	High	Moderate
Perindopril	Strength and combination differentiation	High	Low to moderate
ACE inhibitor combinations	Fixed-dose formats	High	Moderate
ARB products	ODT, combinations, adherence packaging	High	Moderate

Lisinopril has a commercial advantage in familiarity, once-daily use, low cost, and broad generic availability. Its disadvantages include intense price competition and limited room for premium pricing without a meaningful delivery or adherence benefit.

What generic launch scenarios exist for a new lisinopril product?

Scenario 1: Standard immediate-release tablet

This is the lowest-risk regulatory option but also the least attractive commercial option. Success depends on manufacturing cost, wholesaler access, shortage resilience, and reliable supply. Patent risk is low; price erosion is high.

Scenario 2: Differentiated orally disintegrating tablet

This could support a 505(b)(2) or other differentiated regulatory strategy, depending on formulation and claims. The product would need measurable advantages in disintegration, administration, adherence, or patient usability.

Scenario 3: Pediatric dispersible product

This targets a smaller market with less direct competition. The product may gain institutional uptake if it improves dose accuracy and administration for children.

Scenario 4: Stable oral liquid

This has higher technical and regulatory risk but can address long-term care, home health, pediatric, and dysphagia markets. Packaging and stability studies would determine commercial feasibility.

Scenario 5: Combination product

A lisinopril combination can reduce pill burden, but established combinations are heavily commoditized. A new combination requires strong clinical positioning or a delivery advantage.

What is the revenue exposure for PRINIVIL?

The original PRINIVIL brand is not a meaningful growth asset. Revenue exposure is concentrated in generic lisinopril volume, institutional purchasing, and combination products rather than in branded PRINIVIL sales.

For a pharmaceutical company, the economic profile is:

• Low expected brand premium for standard tablets
• High sensitivity to generic price erosion
• Moderate opportunity in differentiated dosage forms
• Potentially higher gross margin for liquid and orally disintegrating products
• Limited value from historical PRINIVIL trademarks alone
• Greater value from manufacturing scale and channel contracts

Exact product-level revenue should not be inferred from the existence of the PRINIVIL name because historical brand sales, generic sales, and lisinopril market sales are separate commercial categories.

What patent strategy is available for a new lisinopril product?

A viable patent program should focus on narrow, technically defensible claims:

1. Specific excipient ratios that improve disintegration or stability.
2. Taste-masking systems with demonstrated dissolution performance.
3. Low-dose uniformity processes.
4. Moisture-resistant packaging and formulation combinations.
5. Stable aqueous compositions.
6. Pediatric dosing systems.
7. Novel fixed-dose combinations.
8. Manufacturing processes that produce a measurable quality advantage.

Method-of-use claims could target defined patient groups, adherence improvement, or administration methods, but such claims may face enforcement and obviousness challenges. A sponsor should avoid relying on broad claims to lisinopril treatment because the underlying indications are established.

Key Takeaways

• PRINIVIL is a legacy lisinopril brand with no meaningful current exclusivity barrier.
• The labeled formulation uses conventional excipients: calcium phosphate, mannitol, starch, magnesium stearate, and selected colorant.
• Standard lisinopril tablets are commercially accessible but highly price competitive.
• The strongest formulation opportunities are orally disintegrating, dispersible, pediatric, liquid, and fixed-dose combination products.
• Excipient suppliers can create value through direct-compression systems, taste masking, moisture control, and low-dose content-uniformity platforms.
• A new patent estate should protect a specific formulation or process, not the conventional lisinopril tablet.
• Paragraph IV and biosimilar risks are limited for ordinary lisinopril tablets. Biosimilars are not relevant because lisinopril is a small-molecule drug.
• Manufacturing reliability, low cost, and distribution access are more important than historical PRINIVIL branding.

FAQs

Is PRINIVIL still commercially available?

PRINIVIL is primarily a legacy brand. Lisinopril remains widely available through generic manufacturers.

Can a company patent a new lisinopril tablet?

Yes. A company may patent a novel formulation, manufacturing process, taste-masking system, stability profile, or delivery format. The conventional lisinopril tablet itself offers limited new patent scope.

Which excipients are best for a lisinopril orally disintegrating tablet?

Mannitol, a suitable superdisintegrant, a low-level binder, and controlled magnesium stearate are common starting points. Taste-masking excipients may be required because lisinopril can have an unpleasant taste.

Does lisinopril have biosimilar competition?

No. Lisinopril is a synthetic small-molecule drug. Competition occurs through generic drugs approved under the ANDA pathway, not through biosimilar applications.

Is a lisinopril liquid formulation commercially attractive?

It can address dysphagia, pediatric, and long-term-care markets, but the opportunity is narrower than for tablets. Chemical stability, preservative control, packaging, and shelf life determine feasibility.

References

1. U.S. Food and Drug Administration. (n.d.). PRINIVIL (lisinopril) tablets prescribing information. DailyMed.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.
3. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations, electronic resources. FDA.
4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application approvals and generic drug guidance. FDA.